 |
|
Hypothalamic Releasing Factors and Parkinson Disease
Thomas N. Chase, MD;
Anne C. Woods, MB, BS;
Morris A. Lipton, MD;
Charles E. Morris, MD
Arch Neurol. 1974;31(1):55-56.
Abstract
Therapeutic trials of intravenously infused thyrotrophin-releasing hormone or melanocyte-stimulating hormone releaseinhibiting factor were conducted in patients with idiopathic parkinsonism. Thyrotrophin-releasing hormone had no consistent effect on extrapyramidal function in five otherwise untreated patients, nor did it significantly modify the response to levodopa in six other individuals. Melanocyte-stimulating hormone release-inhibiting factor exerted a mild amelioratory effect in three of six untreated patients, while in five levodopatreated individuals antiparkinsonian efficacy was potentiated in two and dyskinesias increased in three. In neither group, however, did these effects attain statistical significance.
Author Affiliations
Bethesda, Md; Chapel Hill, NC
From the Neurology Unit, National Institute of Mental Health, Bethesda, Md (Drs. Chase and Woods), and the departments of psychiatry (Dr. Lipton) and neurology (Dr. Morris), University of North Carolina School of Medicine, Chapel Hill.
Footnotes
Accepted for publication Nov 21, 1973.
Reprint requests to Neurology Unit, NIH Clinical Center, 9000 Rockville Pike, Bethesda, Md 20014 (Dr. Chase).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
{alpha}-Melanocyte-Stimulating Hormonelike Immunoreactivity Is Increased in Cerebrospinal Fluid of Patients With Parkinson's Disease
Rainero et al.
Arch Neurol 1988;45:1224-1227.
ABSTRACT
Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials
Mitsumoto et al.
Arch Neurol 1988;45:189-202.
ABSTRACT
|
